Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...

SC lawmakers advanced a bill that would require a disclaimer for COVID-19 vaccinations. Physicians have broadly encouraged ...

Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was available, including among those with underlying conditions or severe disease ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

Pfizer announced Friday that it would submit a request to the FDA Friday for its COVID-19 vaccine to be granted Emergency Use Authorization. Earlier this week, Pfizer said that a final analysis of ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...